Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tumor microenvironment in mycosis fungoides and Sézary syndrome
Belén Rubio González, Jasmine Zain, Steven T. Rosen, et al.
Current Opinion in Oncology (2015) Vol. 28, Iss. 1, pp. 88-96
Closed Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Mycosis Fungoides and Sézary Syndrome
Cecilia Larocca, Thomas S. Kupper
Hematology/Oncology Clinics of North America (2018) Vol. 33, Iss. 1, pp. 103-120
Open Access | Times Cited: 109
Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience
Alecia S. Folkes, Mingye Feng, Jasmine Zain, et al.
Current Opinion in Oncology (2018) Vol. 30, Iss. 5, pp. 332-337
Open Access | Times Cited: 64
CCR4 in cutaneous T‐cell lymphoma: Therapeutic targeting of a pathogenic driver
Jan P. Nicolay, Jana D. Albrecht, Silvia Alberti Violetti, et al.
European Journal of Immunology (2021) Vol. 51, Iss. 7, pp. 1660-1671
Open Access | Times Cited: 42
Role of IL-4 and IL-13 in Cutaneous T Cell Lymphoma
Roberto Mazzetto, Paola Miceli, Jacopo Tartaglia, et al.
Life (2024) Vol. 14, Iss. 2, pp. 245-245
Open Access | Times Cited: 6
STAT5 induces miR-21 expression in cutaneous T cell lymphoma
Lise M. Lindahl, Simon Fredholm, Claudine Joseph, et al.
Oncotarget (2016) Vol. 7, Iss. 29, pp. 45730-45744
Open Access | Times Cited: 49
Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma
Kayo Tanita, Taku Fujimura, Yota Sato, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 44
Pathogenesis and Therapy of Primary Cutaneous T-Cell Lymphoma: Collegium Internationale Allergologicum (CIA) Update 2020
Małgorzata Bobrowicz, Christina Fassnacht, Desislava Ignatova, et al.
International Archives of Allergy and Immunology (2020) Vol. 181, Iss. 10, pp. 733-745
Open Access | Times Cited: 42
Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation
Ieva Saulīte, Desislava Ignatova, Yun‐Tsan Chang, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 40
Molecular pathogenesis of Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathways
Kalyani Patil, Shilpa Kuttikrishnan, Abdul Quaiyoom Khan, et al.
Seminars in Cancer Biology (2021) Vol. 86, pp. 382-399
Open Access | Times Cited: 40
Cellular Interactions and Inflammation in the Pathogenesis of Cutaneous T-Cell Lymphoma
Veronica Stolearenco, Martin R. J. Namini, Siri S. Hasselager, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 39
Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma
Alyxzandria M. Gaydosik, Dawn Queen, Megan H. Trager, et al.
Blood (2020) Vol. 136, Iss. 15, pp. 1748-1759
Open Access | Times Cited: 32
T-cell lymphomas, a challenging disease: types, treatments, and future
Helen Ma, Maher Abdul‐Hay
International Journal of Clinical Oncology (2016) Vol. 22, Iss. 1, pp. 18-51
Open Access | Times Cited: 37
Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration
Jing Jin, Qijie Zhao
Theranostics (2020) Vol. 10, Iss. 14, pp. 6231-6244
Open Access | Times Cited: 28
The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication
Joseph S. Durgin, David M. Weiner, Maria Wysocka, et al.
Journal of the American Academy of Dermatology (2020) Vol. 84, Iss. 3, pp. 587-595
Open Access | Times Cited: 27
Mycosis Fungoides and Sézary Syndrome: Microenvironment and Cancer Progression
Gábor Dobos, Ingrid Lazaridou, Adèle de Masson
Cancers (2023) Vol. 15, Iss. 3, pp. 746-746
Open Access | Times Cited: 10
Spatially Guided and Single Cell Tools to Map the Microenvironment in Cutaneous T-Cell Lymphoma
Eirini Kalliara, Emma Belfrage, Urban Gullberg, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2362-2362
Open Access | Times Cited: 10
Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti–PD-L1 and lenalidomide in cutaneous T cell lymphoma
Zhen Han, Xiwei Wu, Hanjun Qin, et al.
JCI Insight (2023) Vol. 8, Iss. 13
Open Access | Times Cited: 10
Pruritus in Cutaneous T-Cell Lymphoma and Its Management
Linda Serrano, Maria Estela Martínez‐Escala, Xiaolong Zhou, et al.
Dermatologic Clinics (2018) Vol. 36, Iss. 3, pp. 245-258
Closed Access | Times Cited: 29
Novel Immunotherapies for T Cell Lymphoma and Leukemia
Paola Ghione, Alison J. Moskowitz, Nadia E. K. De Paola, et al.
Current Hematologic Malignancy Reports (2018) Vol. 13, Iss. 6, pp. 494-506
Open Access | Times Cited: 29
Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in Sézary syndrome
Florian Anzengruber, Desislava Ignatova, Tanja Schlaepfer, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2019) Vol. 60, Iss. 8, pp. 1899-1907
Open Access | Times Cited: 27
Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives
Gabriele Roccuzzo, Silvia Giordano, Paolo Fava, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 20
Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas
Karol Kołkowski, Magdalena Trzeciak, Małgorzata Sokołowska‐Wojdyło
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13388-13388
Open Access | Times Cited: 20
Expression of immune checkpoint molecules programmed death protein 1, programmed death‐ligand 1 and inducible T‐cell co‐stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome*
Cosimo Di Raimondo, Belén Rubio-González, Joycelynne Palmer, et al.
British Journal of Dermatology (2022) Vol. 187, Iss. 2, pp. 234-243
Open Access | Times Cited: 15
GRK2 mediates TCR-induced transactivation of CXCR4 and TCR–CXCR4 complex formation that drives PI3Kγ/PREX1 signaling and T cell cytokine secretion
Brittney A. Dinkel, Kimberly N. Kremer, Meagan R. Rollins, et al.
Journal of Biological Chemistry (2018) Vol. 293, Iss. 36, pp. 14022-14039
Open Access | Times Cited: 27
ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells
F. Amatore, Nicolás Ortonne, Marc Lopez, et al.
Blood Advances (2020) Vol. 4, Iss. 20, pp. 5203-5214
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top